licensing

News

AZ extends cardiovascular pipeline with $2bn CSPC deal

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut

News

Lungs computer graphic in palm of a doctor's hand

Roivant's new 'vant' emerges to advance Bayer lung drug

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million.

News

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou

News

MSD adds bispecific cancer antibody via $1.3bn Curon deal

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies.

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

News

Ipsen forges another ADC alliance, this time with Foreseen

Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bi

AZ extends cardiovascular pipeline with $2bn CSPC deal

Roivant's new 'vant' emerges to advance Bayer lung drug

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

MSD adds bispecific cancer antibody via $1.3bn Curon deal

Ipsen builds again, licensing Day One glioma drug

Ipsen forges another ADC alliance, this time with Foreseen

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

licensing

Editor's Picks